AstraZeneca has struck a number of deals around the world to supply the experimental COVID-19 vaccine, which has shown promise in early testing.
The company reiterated that it was on track with late-stage trials for its coronavirus vaccine, which could be rolled out by the year-end.
AstraZeneca in June picked Emergent to help produce 300 million doses of its potential COVID-19 vaccine pledged to the United States.
London-listed AstraZeneca said on Monday it would make an upfront payment of $1 billion to Daiichi for an experimental drug called DS-1062, which belongs to a newer class of treatments called antibody drug conjugates (ADC).
With over 1.5 crore people across the globe having contracted the infection, the world is eagerly awaiting a vaccine that would bolster the global fight against COVID-19.
In this edition of the Explained series, find out what it means for the fight against COVID-19.
'There might be a million doses manufactured by September: that now seems like a remarkable underestimate, given the scale of what's going on,' Adrian Hill of University of Oxford said, referring to the manufacturing capability of partner AstraZeneca.
The vaccine did not prompt any serious side effects and elicited antibody and T-cell immune responses
The vaccine called AZD1222 and under development by AstraZeneca and scientists at Britain's Oxford University, did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.
COVAX is co-led by GAVI, the World Health Organization and the CEPI Coalition for Epidemic Preparedness Innovations. Its aim is to deliver 2 billion doses of effective, approved COVID-19 vaccines by the end of 2021.
The developers of the vaccine said this month they are encouraged by the immune response they have seen in trials so far and were expecting to be able to publish Phase 1 data by the end of July.
AstraZeneca director Jorge Mazzei told reporters on Monday that if the vaccine works he believes the hard-hit South American nation will get it at the end of the year. But he has just had the first call with local partners Fiocruz and will start working on a contract on Tuesday.
Soumya Swaminathan said that Moderna's COVID-19 vaccine candidate was ‘not far behind’ Astrazeneca's, among more than 200 candidates, 15 of which have entered clinical trials
The ChAdOx1 nCoV-19 vaccine, also known as AZD1222, was originally developed by Oxford University scientists, who are now working with AstraZeneca on development and production.
The British drugmaker has already begun human trials of the vaccine developed by the University of Oxford, with a phase I trial in Britain due to end soon and a phase III trial already begun, Pascal Soriot told broadcaster Bel RTL.
The contract is for 400 million doses of the vaccine, which was developed with the University of Oxford and whose experimentation phase is already advanced and expected to end in autumn, Roberto Speranza said in a Facebook post.
Such a deal would unite two of the drugmakers at the forefront of the industry's efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.
AstraZeneca has agreed terms with Serum Institute of India to supply one billion doses for low and middle-income countries
AstraZeneca's partnership with Oxford University has garnered international attention as one of the leading coronavirus vaccine candidates, sealing more than $1 billion in U.S. government funding last month as it ramps up testing of the vaccine and manufacturing capacity.
While not yet proven to be effective against the coronavirus, vaccines are seen by world leaders as the only real way to restart their stalled economies, and even to get an edge over global competitors.
While not proven to be effective against the coronavirus, vaccines are seen by many world leaders as the only real way to restart their stalled economies, and even to get an edge over global competitors.
Pharmaceutical and biopharmaceutical company AstraZeneca is expected to start working manufacturing capabilities once the late stage of the COVID-19 vaccine's trials begin.
The combo treatment has been approved in the United States for adult patients with extensive-stage small cell lung cancer, the company said.
The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.
This comes after AstraZeneca said it was launching a new fund with China International Capital Corp to invest $1 billion in China's healthcare sector, as it expands its research work in the country.